Share this

Article Facebook

Twitter

Email You are free to share this article under the Attribution 4.0 International license. University University of Michigan

Researchers are working to improve survival rates in the tiniest, most premature babies with an artificial placenta that mimics the womb.

“We thought, ‘Maybe we should treat this tiny baby like a fetus.'”

The technology has yet to reach the clinical trial stage, but researchers say they are making dramatic progress. An out-of-body artificial placenta has kept five extremely premature lambs alive for a week. The lambs were transferred to the artificial placenta, which utilizes extracorporeal membrane oxygenation (ECMO), without ever taking their first breath.

The ultimate goal of nearly a decade of sustained work: for an artificial placenta to help extremely premature babies with the greatest risks of disability or death continue critical organ development outside of their mother’s womb.

Despite significant advances in the treatment of prematurity, the risk of death and long-term disability remains high for extremely premature infants who are born before 24 weeks. The reason? Their bodies simply are not prepared for life outside the womb.

“One of the gravest risks for extremely premature babies is undeveloped lungs that are too fragile to handle even the gentlest ventilation techniques,” says George Mychaliska, director of the University of Michigan’s Fetal Diagnosis and Treatment Center. “If a baby’s lungs are severely immature, they cannot provide the brain, heart, and other organs the oxygen they need to survive.

“We thought, ‘Why don’t we solve the problem of prematurity by re-creating the intrauterine environment?’'” he says. “Maybe we should treat this tiny baby like a fetus. Maybe we should treat these babies as if they are still in the womb.

“This is a complete paradigm shift. Our research is still in a very preliminary stage, but we’ve passed a significant milestone that gives us promise of revolutionizing the treatment of prematurity. Although many of our current therapies are lifesaving, they are not designed for premature babies and are often ineffective or contribute to complications.”

How it works

The artificial placenta works by simulating the intrauterine environment and providing gas exchange without mechanical ventilation. By recapitulating normal fetal physiology to re-create the intrauterine environment, the artificial placenta holds the promise of normal growth and development outside the womb for extremely premature infants until they are ready for postnatal life.

The success of keeping lambs alive through this technique was a crucial milestone in securing a National Institutes of Health grant to accelerate the research.

Over the next five years, researchers expect to demonstrate that an artificial placenta can simulate the intrauterine environment and support a fetal lamb from extreme prematurity to normal newborn physiology. The next step would be to determine if the milestones would justify preliminary clinical trials in extremely premature babies.

It’s a vision first imagined nearly 50 years ago shortly after the advent of cardiopulmonary bypass, when researchers described the potential of a future artificial placenta in a Life magazine story.

Robert Bartlett, professor emeritus of pediatric surgery known as the “father of ECMO” for developing the lifesaving heart-lung technology, is a contributor to the lab’s work.

“With a better understanding of the physiology of prematurity and advanced technology, we are now in a position to bring this innovative approach envisioned five decades ago to fruition.”

Source: University of Michigan